Artelo Biosciences, Inc. (NASDAQ:ARTL) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Artelo Biosciences, Inc. (NASDAQ:ARTL) have received an average recommendation of “Hold” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $24.00.

A number of research firms have weighed in on ARTL. D. Boral Capital reiterated a “hold” rating on shares of Artelo Biosciences in a research note on Monday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artelo Biosciences in a research report on Monday, December 1st. Maxim Group restated a “hold” rating on shares of Artelo Biosciences in a report on Wednesday, November 19th. Finally, D Boral Capital cut Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th.

Artelo Biosciences Stock Performance

NASDAQ ARTL opened at $1.94 on Friday. Artelo Biosciences has a fifty-two week low of $1.52 and a fifty-two week high of $28.60. The business’s 50 day moving average price is $2.74 and its 200-day moving average price is $6.90. The company has a market cap of $3.92 million, a P/E ratio of -0.09 and a beta of 1.06.

Artelo Biosciences (NASDAQ:ARTL) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($3.97) EPS for the quarter, missing the consensus estimate of ($0.82) by ($3.15). As a group, equities analysts predict that Artelo Biosciences will post -2.62 EPS for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.